vs
ALLURION TECHNOLOGIES, INC.（ALUR）与GLOBUS MEDICAL INC（GMED）财务数据对比。点击上方公司名可切换其他公司
GLOBUS MEDICAL INC的季度营收约是ALLURION TECHNOLOGIES, INC.的228.7倍（$826.4M vs $3.6M）。GLOBUS MEDICAL INC净利率更高（17.0% vs -167.0%，领先184.0%）。GLOBUS MEDICAL INC同比增速更快（25.7% vs -35.4%）。过去两年GLOBUS MEDICAL INC的营收复合增速更高（16.7% vs -38.0%）
罗宾逊科技是一家日本电子游戏开发商，由塞思·罗宾逊创立。该公司开发了《赤龙传说》、《行星：太空探索》等BBS门户游戏，还与Hamumu Software合作开发了实验性多人创意沙盒游戏《成长国度》，该作于2013年在iOS、安卓、Windows和macOS平台推出。
Globus Medical是总部位于美国宾夕法尼亚州奥杜邦的上市骨科医疗器械企业，专注于相关产品的设计、研发与商业化，助力外科医生为肌肉骨骼系统疾病患者提供治疗方案，促进患者康复。
ALUR vs GMED — 直观对比
营收规模更大
GMED
是对方的228.7倍
$3.6M
营收增速更快
GMED
高出61.1%
-35.4%
净利率更高
GMED
高出184.0%
-167.0%
两年增速更快
GMED
近两年复合增速
-38.0%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $3.6M | $826.4M |
| 净利润 | $-6.0M | $140.6M |
| 毛利率 | 44.5% | 68.4% |
| 营业利润率 | -174.2% | 20.5% |
| 净利率 | -167.0% | 17.0% |
| 营收同比 | -35.4% | 25.7% |
| 净利润同比 | 37.2% | 430.4% |
| 每股收益（稀释后） | $-0.69 | $1.01 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ALURGMED
| Q4 25 | $3.6M | $826.4M | ||
| Q3 25 | $2.7M | $769.0M | ||
| Q2 25 | $3.4M | $745.3M | ||
| Q1 25 | $5.6M | $598.1M | ||
| Q4 24 | $5.6M | $657.3M | ||
| Q3 24 | $5.4M | $625.7M | ||
| Q2 24 | $11.8M | $629.7M | ||
| Q1 24 | $9.4M | $606.7M |
净利润ALURGMED
| Q4 25 | $-6.0M | $140.6M | ||
| Q3 25 | $-11.9M | $119.0M | ||
| Q2 25 | $-9.3M | $202.8M | ||
| Q1 25 | $-1.5M | $75.5M | ||
| Q4 24 | $-9.6M | $26.5M | ||
| Q3 24 | $8.7M | $51.8M | ||
| Q2 24 | $-8.3M | $31.8M | ||
| Q1 24 | $2.0M | $-7.1M |
毛利率ALURGMED
| Q4 25 | 44.5% | 68.4% | ||
| Q3 25 | 49.1% | 67.2% | ||
| Q2 25 | 73.9% | 66.6% | ||
| Q1 25 | 74.6% | 67.3% | ||
| Q4 24 | 45.3% | 59.9% | ||
| Q3 24 | 58.0% | 56.8% | ||
| Q2 24 | 76.4% | 58.7% | ||
| Q1 24 | 73.2% | 60.2% |
营业利润率ALURGMED
| Q4 25 | -174.2% | 20.5% | ||
| Q3 25 | -362.3% | 17.9% | ||
| Q2 25 | -205.7% | 10.2% | ||
| Q1 25 | -130.5% | 16.2% | ||
| Q4 24 | -306.2% | 9.2% | ||
| Q3 24 | -229.9% | 7.7% | ||
| Q2 24 | -79.4% | 7.9% | ||
| Q1 24 | -121.4% | 1.3% |
净利率ALURGMED
| Q4 25 | -167.0% | 17.0% | ||
| Q3 25 | -447.1% | 15.5% | ||
| Q2 25 | -276.3% | 27.2% | ||
| Q1 25 | -26.9% | 12.6% | ||
| Q4 24 | -171.8% | 4.0% | ||
| Q3 24 | 162.8% | 8.3% | ||
| Q2 24 | -70.7% | 5.0% | ||
| Q1 24 | 21.3% | -1.2% |
每股收益（稀释后）ALURGMED
| Q4 25 | $-0.69 | $1.01 | ||
| Q3 25 | $-1.53 | $0.88 | ||
| Q2 25 | $-1.28 | $1.49 | ||
| Q1 25 | $-0.31 | $0.54 | ||
| Q4 24 | $-3.22 | $0.19 | ||
| Q3 24 | $3.40 | $0.38 | ||
| Q2 24 | $-4.34 | $0.23 | ||
| Q1 24 | $0.96 | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $5.4M | $557.2M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $-77.2M | $4.6B |
| 总资产 | $15.8M | $5.3B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ALURGMED
| Q4 25 | $5.4M | $557.2M | ||
| Q3 25 | $6.1M | $18.8M | ||
| Q2 25 | $12.7M | — | ||
| Q1 25 | $20.4M | — | ||
| Q4 24 | $15.4M | $890.1M | ||
| Q3 24 | $28.7M | $71.9M | ||
| Q2 24 | $19.3M | $82.5M | ||
| Q1 24 | $29.7M | $80.4M |
股东权益ALURGMED
| Q4 25 | $-77.2M | $4.6B | ||
| Q3 25 | $-82.9M | $4.4B | ||
| Q2 25 | $-64.0M | $4.3B | ||
| Q1 25 | $-69.8M | $4.1B | ||
| Q4 24 | $-78.0M | $4.2B | ||
| Q3 24 | $-64.8M | $4.1B | ||
| Q2 24 | $-70.6M | $4.0B | ||
| Q1 24 | $-66.2M | $3.9B |
总资产ALURGMED
| Q4 25 | $15.8M | $5.3B | ||
| Q3 25 | $18.1M | $5.1B | ||
| Q2 25 | $28.2M | $5.0B | ||
| Q1 25 | $38.4M | $4.7B | ||
| Q4 24 | $32.8M | $5.3B | ||
| Q3 24 | $50.7M | $5.1B | ||
| Q2 24 | $46.5M | $5.0B | ||
| Q1 24 | $60.0M | $4.9B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-5.3M | $248.6M |
| 自由现金流经营现金流 - 资本支出 | — | $202.4M |
| 自由现金流率自由现金流/营收 | — | 24.5% |
| 资本支出强度资本支出/营收 | — | 5.6% |
| 现金转化率经营现金流/净利润 | — | 1.77× |
| 过去12个月自由现金流最近4个季度 | — | $588.8M |
8季度趋势，按日历期对齐
经营现金流ALURGMED
| Q4 25 | $-5.3M | $248.6M | ||
| Q3 25 | $-6.5M | $249.7M | ||
| Q2 25 | $-7.6M | $77.9M | ||
| Q1 25 | $-9.5M | $177.3M | ||
| Q4 24 | $-13.3M | $210.3M | ||
| Q3 24 | $-11.5M | $203.7M | ||
| Q2 24 | $-8.9M | $54.3M | ||
| Q1 24 | $-8.6M | $52.4M |
自由现金流ALURGMED
| Q4 25 | — | $202.4M | ||
| Q3 25 | — | $213.9M | ||
| Q2 25 | — | $31.3M | ||
| Q1 25 | — | $141.2M | ||
| Q4 24 | — | $193.2M | ||
| Q3 24 | $-11.5M | $161.7M | ||
| Q2 24 | $-9.4M | $26.5M | ||
| Q1 24 | $-8.7M | $23.8M |
自由现金流率ALURGMED
| Q4 25 | — | 24.5% | ||
| Q3 25 | — | 27.8% | ||
| Q2 25 | — | 4.2% | ||
| Q1 25 | — | 23.6% | ||
| Q4 24 | — | 29.4% | ||
| Q3 24 | -214.9% | 25.8% | ||
| Q2 24 | -79.6% | 4.2% | ||
| Q1 24 | -93.1% | 3.9% |
资本支出强度ALURGMED
| Q4 25 | — | 5.6% | ||
| Q3 25 | — | 4.7% | ||
| Q2 25 | — | 6.2% | ||
| Q1 25 | — | 6.0% | ||
| Q4 24 | 0.0% | 2.6% | ||
| Q3 24 | 1.3% | 6.7% | ||
| Q2 24 | 3.7% | 4.4% | ||
| Q1 24 | 1.1% | 4.7% |
现金转化率ALURGMED
| Q4 25 | — | 1.77× | ||
| Q3 25 | — | 2.10× | ||
| Q2 25 | — | 0.38× | ||
| Q1 25 | — | 2.35× | ||
| Q4 24 | — | 7.94× | ||
| Q3 24 | -1.31× | 3.93× | ||
| Q2 24 | — | 1.71× | ||
| Q1 24 | -4.33× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ALUR
暂无分部数据
GMED
| Other | $391.8M | 47% |
| Nevro Merger Agreement | $293.6M | 36% |
| Enabling Technologies | $141.0M | 17% |
